공지사항
Autoimmune Inflammatory Rheumatic Diseases 환자에서 COVID-19 접종 권고안
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases
: Clinical Guidance of the Korean College of Rheumatology
1. Currently available COVID-19 vaccines are considered to be non-live vaccines and generally safe in AIIRD patients on immunosuppressive treatment.
2. The risk of disease flare of AIIRD after vaccination is low.
3. Patients with AIIRD should receive a COVID-19 vaccine unless it is contraindicated due to a previous allergic reaction to the vaccine or its components.
: Clinical Guidance of the Korean College of Rheumatology
1. Currently available COVID-19 vaccines are considered to be non-live vaccines and generally safe in AIIRD patients on immunosuppressive treatment.
2. The risk of disease flare of AIIRD after vaccination is low.
3. Patients with AIIRD should receive a COVID-19 vaccine unless it is contraindicated due to a previous allergic reaction to the vaccine or its components.
4. Patients should be monitored at least for 15 minutes after vaccination for anaphylaxis.
5. DMARDs should be continued during vaccination. To improve vaccine efficacy, the timing of RTX, MTX, and ABA administration can be adjusted.
6. General public health measures against COVID-19 infection, such as wearing a mask, hand hygiene, and social distancing, should be continued even after vaccination.
5. DMARDs should be continued during vaccination. To improve vaccine efficacy, the timing of RTX, MTX, and ABA administration can be adjusted.
6. General public health measures against COVID-19 infection, such as wearing a mask, hand hygiene, and social distancing, should be continued even after vaccination.